Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Preeclampsia: Management and prognosis

Errol R Norwitz, MD, PhD, MBA
John T Repke, MD
Section Editor
Charles J Lockwood, MD, MHCM
Deputy Editor
Vanessa A Barss, MD, FACOG


Preeclampsia is a multi-system, progressive disorder characterized by the new onset of hypertension and proteinuria or hypertension and end-organ dysfunction with or without proteinuria in the last half of pregnancy (table 1). Progression from mild to severe on the disease spectrum (table 2) may be gradual or rapid.

A key focus of routine prenatal care is monitoring pregnancies for signs and symptoms of preeclampsia. If the diagnosis is made, the definitive treatment is delivery to prevent development of maternal or fetal complications from disease progression: Delivery results in resolution of the disease. Timing of delivery is based upon a combination of factors, including disease severity, maternal and fetal condition, and gestational age.

This topic will discuss the management of pregnancies complicated by preeclampsia and maternal prognosis. Other important issues related to this disease are reviewed separately.

(See "Preeclampsia: Pathogenesis".)

(See "Preeclampsia: Clinical features and diagnosis".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Nov 29, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Heard AR, Dekker GA, Chan A, et al. Hypertension during pregnancy in South Australia, part 1: pregnancy outcomes. Aust N Z J Obstet Gynaecol 2004; 44:404.
  2. Hauth JC, Ewell MG, Levine RJ, et al. Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. Obstet Gynecol 2000; 95:24.
  3. National Collaborating Centre for Women's and Children's Health. Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy, RCOG Press, London 2010.
  4. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122:1122.
  5. Spong CY, Mercer BM, D'alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011; 118:323.
  6. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 560: Medically indicated late-preterm and early-term deliveries. Obstet Gynecol 2013; 121:908. Reaffirmed 2017.
  7. Magee LA, Pels A, Helewa M, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 2014; 36:416.
  8. Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009; 374:979.
  9. Tajik P, van der Tuuk K, Koopmans CM, et al. Should cervical favourability play a role in the decision for labour induction in gestational hypertension or mild pre-eclampsia at term? An exploratory analysis of the HYPITAT trial. BJOG 2012; 119:1123.
  10. Bernardes TP, Broekhuijsen K, Koopmans CM, et al. Caesarean section rates and adverse neonatal outcomes after induction of labour versus expectant management in women with an unripe cervix: a secondary analysis of the HYPITAT and DIGITAT trials. BJOG 2016; 123:1501.
  11. Vijgen SM, Koopmans CM, Opmeer BC, et al. An economic analysis of induction of labour and expectant monitoring in women with gestational hypertension or pre-eclampsia at term (HYPITAT trial). BJOG 2010; 117:1577.
  12. Broekhuijsen K, van Baaren GJ, van Pampus MG, et al. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. Lancet 2015; 385:2492.
  13. Barton JR, Istwan NB, Rhea D, et al. Cost-savings analysis of an outpatient management program for women with pregnancy-related hypertensive conditions. Dis Manag 2006; 9:236.
  14. Barton JR, Stanziano GJ, Sibai BM. Monitored outpatient management of mild gestational hypertension remote from term. Am J Obstet Gynecol 1994; 170:765.
  15. Turnbull DA, Wilkinson C, Gerard K, et al. Clinical, psychosocial, and economic effects of antenatal day care for three medical complications of pregnancy: a randomised controlled trial of 395 women. Lancet 2004; 363:1104.
  16. Waugh J, Bosio P, Shennan A, Halligan A. Inpatient monitoring on an outpatient basis: managing hypertensive pregnancies in the community using automated technologies. J Soc Gynecol Investig 2001; 8:14.
  17. Helewa M, Heaman M, Robinson MA, Thompson L. Community-based home-care program for the management of pre-eclampsia: an alternative. CMAJ 1993; 149:829.
  18. Dowswell T, Middleton P, Weeks A. Antenatal day care units versus hospital admission for women with complicated pregnancy. Cochrane Database Syst Rev 2009; :CD001803.
  19. Goldenberg RL, Cliver SP, Bronstein J, et al. Bed rest in pregnancy. Obstet Gynecol 1994; 84:131.
  20. Abdul Sultan A, West J, Tata LJ, et al. Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England. BMJ 2013; 347:f6099.
  21. Gordon A, Raynes-Greenow C, Bond D, et al. Sleep position, fetal growth restriction, and late-pregnancy stillbirth: the Sydney stillbirth study. Obstet Gynecol 2015; 125:347.
  22. Schiff E, Friedman SA, Kao L, Sibai BM. The importance of urinary protein excretion during conservative management of severe preeclampsia. Am J Obstet Gynecol 1996; 175:1313.
  23. Hall DR, Odendaal HJ, Steyn DW, Grové D. Urinary protein excretion and expectant management of early onset, severe pre-eclampsia. Int J Gynaecol Obstet 2002; 77:1.
  24. von Dadelszen P, Payne B, Li J, et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 2011; 377:219.
  25. Lindheimer MD, Kanter D. Interpreting abnormal proteinuria in pregnancy: the need for a more pathophysiological approach. Obstet Gynecol 2010; 115:365.
  26. Unger C, Biedermann K, Szloboda J, et al. [Sodium concentration and pre-eclampsia: is salt restriction of value?]. Z Geburtshilfe Neonatol 1998; 202:97.
  27. Nabeshima K. [Effect of salt restriction on preeclampsia]. Nihon Jinzo Gakkai Shi 1994; 36:227.
  28. Mattar F, Sibai BM. Prevention of preeclampsia. Semin Perinatol 1999; 23:58.
  29. Ganzevoort W, Rep A, Bonsel GJ, et al. A randomised controlled trial comparing two temporising management strategies, one with and one without plasma volume expansion, for severe and early onset pre-eclampsia. BJOG 2005; 112:1358.
  30. Alfirevic Z, Stampalija T, Gyte GM. Fetal and umbilical Doppler ultrasound in high-risk pregnancies. Cochrane Database Syst Rev 2010; :CD007529.
  31. Chang EY, Menard MK, Vermillion ST, et al. The association between hyaline membrane disease and preeclampsia. Am J Obstet Gynecol 2004; 191:1414.
  32. Langenveld J, Ravelli AC, van Kaam AH, et al. Neonatal outcome of pregnancies complicated by hypertensive disorders between 34 and 37 weeks of gestation: a 7 year retrospective analysis of a national registry. Am J Obstet Gynecol 2011; 205:540.e1.
  33. Coppage KH, Polzin WJ. Severe preeclampsia and delivery outcomes: is immediate cesarean delivery beneficial? Am J Obstet Gynecol 2002; 186:921.
  34. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180:499.
  35. Amorim MM, Souza ASR, Katz L. Planned caesarean section versus planned vaginal birth for severe pre-eclampsia. Cochrane Database Syst Rev 2017; 10:CD009430.
  36. Nassar AH, Adra AM, Chakhtoura N, et al. Severe preeclampsia remote from term: labor induction or elective cesarean delivery? Am J Obstet Gynecol 1998; 179:1210.
  37. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003; 102:181.
  38. Alexander JM, Bloom SL, McIntire DD, Leveno KJ. Severe preeclampsia and the very low birth weight infant: is induction of labor harmful? Obstet Gynecol 1999; 93:485.
  39. Li YH, Novikova N. Pulmonary artery flow catheters for directing management in pre-eclampsia. Cochrane Database Syst Rev 2012; :CD008882.
  40. Anthony J, Schoeman LK. Fluid management in pre-eclampsia. Obstet Med 2013; 6:100.
  41. Altman D, Carroli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359:1877.
  42. Livingston JC, Livingston LW, Ramsey R, et al. Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol 2003; 101:217.
  43. Witlin AG, Sibai BM. Magnesium sulfate therapy in preeclampsia and eclampsia. Obstet Gynecol 1998; 92:883.
  44. Coetzee EJ, Dommisse J, Anthony J. A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol 1998; 105:300.
  45. Roberts JM, Villar J, Arulkumaran S. Preventing and treating eclamptic seizures. BMJ 2002; 325:609.
  46. Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev 2010; :CD000025.
  47. Duley L, Gulmezoglu AM. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database Syst Rev 2001; :CD002960.
  48. Duley L, Henderson-Smart D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev 2003; :CD000127.
  49. Duley L, Henderson-Smart D. Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev 2003; :CD000128.
  50. Hallak M. Effect of parenteral magnesium sulfate administration on excitatory amino acid receptors in the rat brain. Magnes Res 1998; 11:117.
  51. Cotton DB, Hallak M, Janusz C, et al. Central anticonvulsant effects of magnesium sulfate on N-methyl-D-aspartate-induced seizures. Am J Obstet Gynecol 1993; 168:974.
  52. Belfort MA, Clark SL, Sibai B. Cerebral hemodynamics in preeclampsia: cerebral perfusion and the rationale for an alternative to magnesium sulfate. Obstet Gynecol Surv 2006; 61:655.
  53. Safe Motherhood Initiative. Maternal safety bundle for severe hypertension in pregnancy, November 2015. https://www.acog.org/-/media/Districts/District-II/Public/SMI/v2/HTNSlideSetNov2015Updated.pdf?dmc=1&ts=20161117T1126427528 (Accessed on November 20, 2016).
  54. Duley L, Matar HE, Almerie MQ, Hall DR. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Cochrane Database Syst Rev 2010; :CD007388.
  55. Hall DR, Odendaal HJ, Smith M. Is the prophylactic administration of magnesium sulphate in women with pre-eclampsia indicated prior to labour? BJOG 2000; 107:903.
  56. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol 2004; 190:1520.
  57. FDA recommends against prolonged use of magnesium sulfate to stop pre-term labor due to bone changes in exposed babies. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM353335.pdf (Accessed on May 30, 2013).
  58. Alexander JM, McIntire DD, Leveno KJ, Cunningham FG. Selective magnesium sulfate prophylaxis for the prevention of eclampsia in women with gestational hypertension. Obstet Gynecol 2006; 108:826.
  59. Okusanya BO, Oladapo OT, Long Q, et al. Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia. BJOG 2016; 123:356.
  60. Sibai BM, Lipshitz J, Anderson GD, Dilts PV Jr. Reassessment of intravenous MgSO4 therapy in preeclampsia-eclampsia. Obstet Gynecol 1981; 57:199.
  61. Taber EB, Tan L, Chao CR, et al. Pharmacokinetics of ionized versus total magnesium in subjects with preterm labor and preeclampsia. Am J Obstet Gynecol 2002; 186:1017.
  62. Brookfield KF, Su F, Elkomy MH, et al. Pharmacokinetics and placental transfer of magnesium sulfate in pregnant women. Am J Obstet Gynecol 2016; 214:737.e1.
  63. Szal SE, Croughan-Minihane MS, Kilpatrick SJ. Effect of magnesium prophylaxis and preeclampsia on the duration of labor. Am J Obstet Gynecol 1999; 180:1475.
  64. Belfort MA, Anthony J, Saade GR, et al. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med 2003; 348:304.
  65. Cholst IN, Steinberg SF, Tropper PJ, et al. The influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects. N Engl J Med 1984; 310:1221.
  66. Smith JM, Lowe RF, Fullerton J, et al. An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management. BMC Pregnancy Childbirth 2013; 13:34.
  67. Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. Clin Pharmacokinet 2000; 38:305.
  68. Web-based integrated 2010 & 2015 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 10: Special circumstances of resuscitation. https://eccguidelines.heart.org/index.php/circulation/cpr-ecc-guidelines-2/part-10-special-circumstances-of-resuscitation/ (Accessed on November 20, 2016).
  69. Duffy CR, Odibo AO, Roehl KA, et al. Effect of magnesium sulfate on fetal heart rate patterns in the second stage of labor. Obstet Gynecol 2012; 119:1129.
  70. Gray SE, Rodis JF, Lettieri L, et al. Effect of intravenous magnesium sulfate on the biophysical profile of the healthy preterm fetus. Am J Obstet Gynecol 1994; 170:1131.
  71. Magee LA, Miremadi S, Li J, et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol 2005; 193:153.
  72. Ehrenberg HM, Mercer BM. Abbreviated postpartum magnesium sulfate therapy for women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol 2006; 108:833.
  73. Ascarelli MH, Johnson V, May WL, et al. Individually determined postpartum magnesium sulfate therapy with clinical parameters to safely and cost-effectively shorten treatment for pre-eclampsia. Am J Obstet Gynecol 1998; 179:952.
  74. Isler CM, Barrilleaux PS, Rinehart BK, et al. Repeat postpartum magnesium sulfate administration for seizure prophylaxis: is there a patient profile predictive of need for additional therapy? J Matern Fetal Neonatal Med 2002; 11:75.
  75. Isler CM, Barrilleaux PS, Rinehart BK, et al. Postpartum seizure prophylaxis: using maternal clinical parameters to guide therapy. Obstet Gynecol 2003; 101:66.
  76. Fontenot MT, Lewis DF, Frederick JB, et al. A prospective randomized trial of magnesium sulfate in severe preeclampsia: use of diuresis as a clinical parameter to determine the duration of postpartum therapy. Am J Obstet Gynecol 2005; 192:1788.
  77. Miles JF Jr, Martin JN Jr, Blake PG, et al. Postpartum eclampsia: a recurring perinatal dilemma. Obstet Gynecol 1990; 76:328.
  78. Webert KE, Mittal R, Sigouin C, et al. A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood 2003; 102:4306.
  79. Allford SL, Hunt BJ, Rose P, et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120:556.
  80. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 166: Thrombocytopenia in Pregnancy. Obstet Gynecol 2016; 128:e43.
  81. Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015; 162:205.
  82. Pourrat O, Dorey M, Ragot S, et al. High-Dose Methylprednisolone to Prevent Platelet Decline in Preeclampsia: A Randomized Controlled Trial. Obstet Gynecol 2016; 128:153.
  83. Woudstra DM, Chandra S, Hofmeyr GJ, Dowswell T. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane Database Syst Rev 2010; :CD008148.
  84. Wallace DH, Leveno KJ, Cunningham FG, et al. Randomized comparison of general and regional anesthesia for cesarean delivery in pregnancies complicated by severe preeclampsia. Obstet Gynecol 1995; 86:193.
  85. Estcourt LJ, Ingram C, Doree C, et al. Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia. Cochrane Database Syst Rev 2016; :CD011980.
  86. Berks D, Steegers EA, Molas M, Visser W. Resolution of hypertension and proteinuria after preeclampsia. Obstet Gynecol 2009; 114:1307.
  87. van Oostwaard MF, Langenveld J, Schuit E, et al. Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis. Am J Obstet Gynecol 2015; 212:624.e1.
  88. Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol 2008; 112:359.
  89. Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991; 165:1408.
  90. van Rijn BB, Hoeks LB, Bots ML, et al. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol 2006; 195:723.
  91. Bramham K, Briley AL, Seed P, et al. Adverse maternal and perinatal outcomes in women with previous preeclampsia: a prospective study. Am J Obstet Gynecol 2011; 204:512.e1.
  92. Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol 1986; 155:1011.
  93. Campbell DM, MacGillivray I, Carr-Hill R. Pre-eclampsia in second pregnancy. Br J Obstet Gynaecol 1985; 92:131.
  94. Xiong X, Fraser WD, Demianczuk NN. History of abortion, preterm, term birth, and risk of preeclampsia: a population-based study. Am J Obstet Gynecol 2002; 187:1013.
  95. Sibai BM, Sarinoglu C, Mercer BM. Eclampsia. VII. Pregnancy outcome after eclampsia and long-term prognosis. Am J Obstet Gynecol 1992; 166:1757.
  96. Mostello D, Kallogjeri D, Tungsiripat R, Leet T. Recurrence of preeclampsia: effects of gestational age at delivery of the first pregnancy, body mass index, paternity, and interval between births. Am J Obstet Gynecol 2008; 199:55.e1.
  97. McDonald SD, Best C, Lam K. The recurrence risk of severe de novo pre-eclampsia in singleton pregnancies: a population-based cohort. BJOG 2009; 116:1578.
  98. Trogstad L, Skrondal A, Stoltenberg C, et al. Recurrence risk of preeclampsia in twin and singleton pregnancies. Am J Med Genet A 2004; 126A:41.
  99. Rodger MA, Gris JC, de Vries JIP, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet 2016; 388:2629.
  100. Ananth CV, Peltier MR, Chavez MR, et al. Recurrence of ischemic placental disease. Obstet Gynecol 2007; 110:128.
  101. Ananth CV, Vintzileos AM. Ischemic placental disease: epidemiology and risk factors. Eur J Obstet Gynecol Reprod Biol 2011; 159:77.
  102. Chang JJ, Muglia LJ, Macones GA. Association of early-onset pre-eclampsia in first pregnancy with normotensive second pregnancy outcomes: a population-based study. BJOG 2010; 117:946.
  103. Wikström AK, Stephansson O, Cnattingius S. Previous preeclampsia and risks of adverse outcomes in subsequent nonpreeclamptic pregnancies. Am J Obstet Gynecol 2011; 204:148.e1.
  104. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. J Am Coll Cardiol 2011; 57:1404.
  105. Kessous R, Shoham-Vardi I, Pariente G, et al. Long-term maternal atherosclerotic morbidity in women with pre-eclampsia. Heart 2015; 101:442.
  106. Seely EW, Rich-Edwards J, Lui J, et al. Risk of future cardiovascular disease in women with prior preeclampsia: a focus group study. BMC Pregnancy Childbirth 2013; 13:240.
  107. Wilkins-Haug L, Celi A, Thomas A, et al. Recognition by Women's Health Care Providers of Long-Term Cardiovascular Disease Risk After Preeclampsia. Obstet Gynecol 2015; 125:1287.
  108. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335:974.
  109. McDonald SD, Malinowski A, Zhou Q, et al. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008; 156:918.
  110. Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and Future Cardiovascular Health. A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes 2017; 10.
  111. Behrens I, Basit S, Lykke JA, et al. Association Between Hypertensive Disorders of Pregnancy and Later Risk of Cardiomyopathy. JAMA 2016; 315:1026.
  112. Magnussen EB, Vatten LJ, Lund-Nilsen TI, et al. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. BMJ 2007; 335:978.
  113. Magnussen EB, Vatten LJ, Smith GD, Romundstad PR. Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet Gynecol 2009; 114:961.
  114. Romundstad PR, Magnussen EB, Smith GD, Vatten LJ. Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation 2010; 122:579.
  115. Bytautiene E, Bulayeva N, Bhat G, et al. Long-term alterations in maternal plasma proteome after sFlt1-induced preeclampsia in mice. Am J Obstet Gynecol 2013; 208:388.e1.
  116. Chambers JC, Fusi L, Malik IS, et al. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001; 285:1607.
  117. Agatisa PK, Ness RB, Roberts JM, et al. Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. Am J Physiol Heart Circ Physiol 2004; 286:H1389.
  118. Lampinen KH, Rönnback M, Kaaja RJ, Groop PH. Impaired vascular dilatation in women with a history of pre-eclampsia. J Hypertens 2006; 24:751.
  119. Yinon Y, Kingdom JC, Odutayo A, et al. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation 2010; 122:1846.
  120. Hermes W, Ket JC, van Pampus MG, et al. Biochemical cardiovascular risk factors after hypertensive pregnancy disorders: a systematic review and meta-analysis. Obstet Gynecol Surv 2012; 67:793.
  121. Kaaja RJ, Pöyhönen-Alho MK. Insulin resistance and sympathetic overactivity in women. J Hypertens 2006; 24:131.
  122. Kaaja RJ, Greer IA. Manifestations of chronic disease during pregnancy. JAMA 2005; 294:2751.
  123. Stekkinger E, Zandstra M, Peeters LL, Spaanderman ME. Early-onset preeclampsia and the prevalence of postpartum metabolic syndrome. Obstet Gynecol 2009; 114:1076.
  124. Zandstra M, Stekkinger E, van der Vlugt MJ, et al. Cardiac diastolic dysfunction and metabolic syndrome in young women after placental syndrome. Obstet Gynecol 2010; 115:101.
  125. van Rijn BB, Nijdam ME, Bruinse HW, et al. Cardiovascular disease risk factors in women with a history of early-onset preeclampsia. Obstet Gynecol 2013; 121:1040.
  126. Hooijschuur MC, Ghossein-Doha C, Al-Nasiry S, Spaanderman ME. Maternal metabolic syndrome, preeclampsia, and small for gestational age infancy. Am J Obstet Gynecol 2015; 213:370.e1.
  127. Berks D, Hoedjes M, Raat H, et al. Risk of cardiovascular disease after pre-eclampsia and the effect of lifestyle interventions: a literature-based study. BJOG 2013; 120:924.
  128. Feig DS, Shah BR, Lipscombe LL, et al. Preeclampsia as a risk factor for diabetes: a population-based cohort study. PLoS Med 2013; 10:e1001425.
  129. Lykke JA, Langhoff-Roos J, Sibai BM, et al. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 2009; 53:944.
  130. Callaway LK, Lawlor DA, O'Callaghan M, et al. Diabetes mellitus in the 21 years after a pregnancy that was complicated by hypertension: findings from a prospective cohort study. Am J Obstet Gynecol 2007; 197:492.e1.
  131. Engeland A, Bjørge T, Daltveit AK, et al. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway. Eur J Epidemiol 2011; 26:157.
  132. Vikse BE, Irgens LM, Leivestad T, et al. Preeclampsia and the risk of end-stage renal disease. N Engl J Med 2008; 359:800.
  133. Wang IK, Muo CH, Chang YC, et al. Association between hypertensive disorders during pregnancy and end-stage renal disease: a population-based study. CMAJ 2013; 185:207.
  134. Levine RJ, Vatten LJ, Horowitz GL, et al. Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ 2009; 339:b4336.
  135. Wilson KL, Casey BM, McIntire DD, et al. Subclinical thyroid disease and the incidence of hypertension in pregnancy. Obstet Gynecol 2012; 119:315.
Topic Outline